Showing results (141-150 of 151) with videos related to
Sort By:
Pageof 16
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2020
COP1 destabilizes DELLA proteins in <i>Arabidopsis</i>Noel Blanco-Touriñán, Martina Legris, Eugenio G Minguet, et al.Blood|December 15, 2010
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimensPau Montesinos, Chelo Rayón, Edo Vellenga, et al.Journal of Medicinal Chemistry|July 20, 2023
C-2 Thiophenyl Tryptophan Trimers Inhibit Cellular Entry of SARS-CoV-2 through Interaction with the Viral Spike (S) ProteinMarta Gargantilla, Clara Francés, Anmol Adhav, et al.Plos Pathogens|November 23, 2022
Correction: The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutationTiziana Ginex, Clara Marco-Marín, Miłosz Wieczór, et al.Plos Pathogens|July 11, 2022
The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutationTiziana Ginex, Clara Marco-Marín, Miłosz Wieczór, et al.Breast (Edinburgh, Scotland)|June 17, 2026
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world studyTal Sella, Frederieke van Duijnhoven, Hans Wildiers, et al.Breast (Edinburgh, Scotland)|December 12, 2025
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapyAyelet Shai, Hans Wildiers, Claudio Venieri, et al.American Journal of Hematology|June 30, 2026
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II TrialTeresa Bernal, Javier Zambrano Márquez, Rebeca Rodríguez-Veiga, et al.Breast (Edinburgh, Scotland)|October 7, 2022
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trialJavier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, et al.Frontiers in Oncology|March 12, 2026
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern SpainAlejandro Falcón-González, Elisenda Llabrés-Valenti, Fernando Henao-Carrasco, et al.Pageof 16